Sophion Bioscience gets new capital injection  

2003.01.27
Copenhagen-based Sophion Bioscience has received a fresh capital injection to keep the start-up company going for a further year of operation

Copenhagen-based Sophion Bioscience has received a fresh capital injection to keep the start-up company and its 32 employees going for a further year of operation, with most of the new financing coming from existing investors. Sophion Bioscience works with ion-channel technology for drug development. In Q3 this year the company expects to launch a microchip-based core product, QPatch, which Sophion believes could significantly change the process of drug discovery.

 

Sophion Bioscience was established in 2000 as a spin-off from NeuroSearch, on whose ion-channel technology platform QPatch is based. Prior to the new capital injection, Sophion Bioscience's shareholders consisted of NeuroSearch, Medicon Valley Capital, A/S Dansk Erhvervsinvestering, Dansk Kapitalanlæg Aktieselskab and the US investment company Baker/Tisch Investments. The management and staff also have shares in the company. The news is reported by BiotechDenmark.dk

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×